Advanced search
Publication Cover
Journal of Market Access & Health Policy Volume 7, 2019 - Issue 1
Journal homepage
4,408
Views
30
CrossRef citations to date
0
Altmetric
Original Research Article

Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation

Craig I. ColemanSchool of Pharmacy, University of Connecticut, Storrs, CT, USAView further author information
,
Jean-Baptiste BriereHealth Economist, Bayer AG, Berlin, GermanyCorrespondence[email protected]
View further author information
,
Laurent FauchierCardiologie, Centre Hospitalier Universitaire Trousseau et Université François Rabelais, Tours, FranceView further author information
,
Pierre LevyLEDa-LEGOS, Université Paris-Dauphine, PSL Research University, Paris, FranceView further author information
,
Kevin BowrinHEOR CV, Bayer Plc, Reading, UKView further author information
,
Mondher ToumiFaculty of Medicine, University of Aix-Marseille, Marseille, FranceView further author information
,
Aurélie MillierHEOR Department, HTA Team, Creativ-Ceutical, Paris, FranceView further author information
,
Vanessa TaiebHEOR Department, Evidence Synthesis Team, Creativ-Ceutical, London, UKView further author information
&
Olivia WuHEHTA, University of Glasgow, Glasgow, UKView further author information
 show all
Article: 1574541 | Received 04 Sep 2018, Accepted 18 Jan 2019, Published online: 04 Feb 2019

References

  • Fuster V, Rydén LE, Cannom DS. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation–executive summary. Circulation. 2006;114(7):700–7.
  • Bajpai A, Savelieva I, Camm J. Epidemiology and economic burden of atrial fibrillation. US Cardiol. 2007;4(1):14–17.
  • Bunch TJ, Gersh BJ. Rhythm control strategies and the role of antiarrhythmic drugs in the management of atrial fibrillation: focus on clinical outcomes. J Gen Intern Med. 2011;26(5):531–537.
  • Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016;50(5):e1–e88.
  • Compendium EM. SPC. Warfarin 0.5 mg tablets. 2017 [cited 2017 Oct]. Available from: https://www.medicines.org.uk/emc/medicine/27651
  • Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
  • Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
  • Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
  • Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104.
  • Reviews, U.o.Y.N.C.f. and Dissemination. Systematic reviews: CRD’s guidance for undertaking reviews in health care. York, UK: Centre for Reviews and Dissemination; 2009.  Available from: https://www.york.ac.uk/media/crd/Systematic_Reviews.pdf.
  • Higgins JPT and Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration; 2011. Available from: https://training.cochrane.org/handbook.
  • Briere J-B, Bowrin K, Coleman C, et al. Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2018;19:1–10. DOI: 10.1080/14737167.2018.1518134.
  • Gillies CL, Abrams KR, Lambert PC, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ. 2007;334(7588):299.
  • Silverman SL. From randomized controlled trials to observational studies. Am J Med. 2009;122(2):114–120.
  • Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5(6):e003725.
  • Proietti M, Romanazzi I, Romiti GF, et al. Real-world use of apixaban for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke. 2018;49(1):98–106.
  • Seeger JD, Bykov K, Bartels DB, et al. Propensity score weighting compared to matching in a study of dabigatran and warfarin. Drug Saf. 2017;40(2):169–181.
  • Bassand JP, Accetta G, Camm AJ, et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J. 2016;37(38):2882–2889.
  • Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.